Laboratoires Euromedis

As of December 31, 2025, Laboratoires Euromedis carries a market capitalization of 11.22M, placing it among publicly traded companies globally. Its enterprise value stands at 658,979.05, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Laboratoires Euromedis's next confirmed earnings release is scheduled for March 3, 2027.

As of December 31, 2025, Laboratoires Euromedis has 2.86M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Laboratoires Euromedis maintains a current ratio of 3.36, meaning it holds 3.4x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on August 10, 2026, Laboratoires Euromedis's stock has gained approximately 15.56% over the past 52 weeks. The 50-day moving average sits at 5.42, while the 200-day moving average is 9.16.

As of December 31, 2025, Laboratoires Euromedis holds 16.67M in cash and equivalents against 6.11M in total debt, resulting in a net debt position of -10.57M. Total book value stands at 16.41M, with working capital of 26.88M providing operational flexibility.

Laboratoires Euromedis's most recent stock split took place on March 3, 2011.